Search for:

In brief

The Health Pod, Baker McKenzie’s industry podcast series, highlights sector-specific issues and trends that affect healthcare and life sciences companies.


Episode 7: The ins and outs of handling material non-public information

Healthcare and life sciences are among the most heavily regulated industries, and the US Securities and Exchange Commission continues to focus on healthcare and life sciences companies when it comes to disclosure and reporting requirements. If not managed carefully, the treatment and misuse of material non-public information can expose firms to significant liability and reputational risks. In this episode of The Health Pod, Amy Greer and Carol Stubblefield join David Wardell to discuss best practices when managing material non-public information including determinations of materiality, disclosure obligations, insider trading policies and 10b5-1 plans.

https://open.spotify.com/embed-podcast/episode/5ALhqbwBsHjPH2PjRQYnb7

Related podcasts

Episode 1 Canada: Health Canada and the FDA’s response to COVID-19 (Podcast)

Episode 2 EU and Mexico: COVID-19 Impact on biopharma clinical development in the EU and Mexico (Podcast)

Episode 3 International: Alternative arrangements for biopharma clinical funding (Podcast)

Episode 4 Europe: UK and EU Competition law in times of COVID-19 and beyond (Podcast)

Episode 5 Japan: Pharmaceuticals market – Distinguishing features and industry practice (Podcast)

Episode 6 Japan: Pharmaceuticals market – Regulatory landscape (Podcast)

Author

Amy serves as the Co-chair of Baker McKenzie’s North American Financial Regulation and Enforcement Practice, which provides our clients with a full range of regulatory advice and enforcement counseling. Previously, Amy has served as chief litigation counsel at the US Securities and Exchange Commission's (SEC) Philadelphia regional office and managed a team of lawyers overseeing a wide variety of enforcement matters and investigations.

Author

Carol B. Stubblefield is a member of the Firm’s North American Corporate & Securities Practice Group in the New York office. Ms. Stubblefield regularly represents public companies, issuers and underwriters in connection with public and private offerings of debt and equity securities. Ms. Stubblefield provides general corporate counseling and corporate governance advice. She advises companies on M&A transactions, including complex cross-border acquisitions and divestures. She also advises on pre and post transaction restructuring activities. Carol regularly advises on pro bono matters and is active in the Firm's community service efforts.

Author

David Wardell has been practicing law since 1982, mainly in the area of international corporate and commercial law. He serves on the steering committee of both the Global Healthcare Industry Group and the North America Healthcare Industry Group. He is also the Chicago office representative of the Firm’s French Initiative. Prior to joining the Firm, Mr. Wardell practiced for over 26 years first as an Assistant District Attorney in Manhattan under Robert Morgenthau and then at Bristol-Myers Squibb Company, Abbott Laboratories and Tenneco Inc., where he served as general counsel and chief compliance officer.

Write A Comment